P300 latency changes in patients with mild cognitive impairment after taking choline alphoscerate; A preliminary study.

about

P300 latency changes in patients with mild cognitive impairment after taking choline alphoscerate; A preliminary study.

Item

http://www.wikidata.org/entity/Q55339681

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

P300 latency changes in patien ...... oscerate; A preliminary study.

@en

P300 latency changes in patien ...... oscerate; A preliminary study.

@nl

type

Item

label

P300 latency changes in patien ...... oscerate; A preliminary study.

@en

P300 latency changes in patien ...... oscerate; A preliminary study.

@nl

prefLabel

P300 latency changes in patien ...... oscerate; A preliminary study.

@en

P300 latency changes in patien ...... oscerate; A preliminary study.

@nl

P1476

P300 latency changes in patien ...... hoscerate; A preliminary study

@en

P2093

Hae-Bong Jeong

http://www.w3.org/2001/XMLSchema#string

Hae-Won Shin

http://www.w3.org/2001/XMLSchema#string

Kwang-Yeol Park

http://www.w3.org/2001/XMLSchema#string

SangYun Kim

http://www.w3.org/2001/XMLSchema#string

Su-Hyun Han

http://www.w3.org/2001/XMLSchema#string

P2860

P300 development across the lifespan: a systematic review and meta-analysis

Mild cognitive impairment as a diagnostic entity

Cholinergic precursors in the treatment of cognitive impairment of vascular origin: ineffective approaches or need for re-evaluation?

Mild cognitive impairment as a clinical entity and treatment target.

Choline alphoscerate (alpha-glyceryl-phosphoryl-choline) an old choline- containing phospholipid with a still interesting profile as cognition enhancing agent.

Treatment for mild cognitive impairment: a systematic review and meta-analysis

P300 evoked potential in patients with mild cognitive impairment

Subtype of mild cognitive impairment and progression to dementia and death.

P300 latency reflects the degree of cognitive decline in dementing illness.

The ASCOMALVA (Association between the Cholinesterase Inhibitor Donepezil and the Cholinergic Precursor Choline Alphoscerate in Alzheimer's Disease) Trial: interim results after two years of treatment.

P304

5-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.ENSCI.2018.04.004

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Young Chul Youn

P577

2018-04-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29928709

http://www.w3.org/2001/XMLSchema#string

P932

6007142

http://www.w3.org/2001/XMLSchema#string